Fungal biofilms, as self-produced extracellular polymeric substances that resist antifungal agents and immune defense, represent a major cause of treatment failure and recurrent infections. Therefore, it is of great importance to eradicate fungal biofilms to achieve efficient therapy. This study develops a synergistic reactive oxygen species (ROS)-enhanced strategy to eradicate Candida albicans biofilms by designing ultrasound-light dual-responsive nanohybrids (UCNP@CR). The system integrates thulium-doped upconversion nanoparticles (UCNPs) with carbon nitride-coated surfaces (g-C3N4) and polypyridine ruthenium complex (Ru) photosensitizers. In treatment, the dense fungal biofilm can be effectively loosened under ultrasound stimulation while ultrasound simultaneously triggers ROS production of UCNP@CR, collectively promoting irreversible destruction of biofilm and inward penetration of photosensitizer. Moreover, UCNP@CR exhibits strong fungal adhesion, while its g-C3N4-mediated enhanced metal-to-ligand charge transfer (MLCT) process of Ru under near-infrared light irradiation amplifies ROS generation, which leads to efficient eradication of fungal biofilms. As in vivo experimental evidence, UCNP@CR exhibits excellent antifungal efficacy in treating fungal biofilm-infected wounds in immunosuppressed male mice under ultrasound-light stimulation. These findings establish the ultrasound-assisted, ROS-enhanced synergistic strategy as a promising approach against fungal biofilm infections and provide diverse perspective for managing other biofilm-related infectious diseases.
Rapid detection of multibacterial pathogens is crucial for accelerating the diagnosis and treatment of bacterial infections. We propose a rapid and efficient electrochemiluminescence (ECL) sensor for the synchronous detection of multiple bacterial pathogens, including Staphylococcus aureus , Klebsiella pneumoniae , Pseudomonas aeruginosa , and methicillin-resistant S. aureus . This homogeneous sensor is based on a self-assembled DNA nanosphere loaded with tetrakis (4-carboxyphenyl) porphyrin (TCPP). The sensor operates in an “off-on” mode, in which bacterium-aptamer binding triggers a conformational change in the DNA nanosphere, releasing TCPP and generating an enhanced ECL signal. The inclusion of cerium nanoparticles boosts signal intensity through electrocatalytic reactions, improving sensitivity with a detection limit of ≤100 colony-forming units per milliliter. Integrated with a microfluidic chip, the system enables multibacterial detection in just 45 minutes. Bacterial quantification in clinical samples strongly correlates with digital polymerase chain reaction results. This approach provides a rapid, specific, and efficient diagnostic tool for bacterial infections with great potential for point-of-care applications in clinical settings.
The emergence of monkeypox has become a global health threat after the COVID‐19 pandemic. Due to the lack of available specifically treatment against MPV, developing an available vaccine is thus the most prospective and urgent strategy. Herein, a programmable macrophage vesicle based bionic self‐adjuvanting vaccine (AM@AEvs‐PB) is first developed for defending against monkeypox virus (MPV). Based on MPV‐related antigen‐stimulated macrophage‐derived vesicles, the nanovaccine is constructed by loading the mature virion (MV)‐related intracellular protein (A29L/M1R) and simultaneously modifying with the enveloped virion (EV) antigen (B6R), enabling them to effectively promote antigen presentation and enhance adaptive immune through self‐adjuvant strategy. Owing to the synergistic properties of bionic vaccine coloaded MV and EV protein in defensing MPV, the activation ratio of antigen‐presenting cells is nearly four times than that of single antigen in the same dose, resulting in stronger immunity in host. Notably, intramuscular injection uptake of AM@AEvs‐PB demonstrated vigorous immune‐protective effects in the mouse challenge attempt, offering a promising strategy for pre‐clinical monkeypox vaccine development.